Cinnamon Cancer Research Results

Cin, Cinnamon: Click to Expand ⟱
Features:
Cinnamon is a spice from inner bark from several tree species.
Cinnamon refers primarily to bark extracts from Cinnamomum verum (Ceylon cinnamon) and Cinnamomum cassia. Bioactive constituents include cinnamaldehyde, cinnamic acid derivatives, procyanidins, and polyphenols. In cancer models, cinnamon extracts and cinnamaldehyde are most frequently reported to exert anti-proliferative, pro-apoptotic, anti-inflammatory, and anti-angiogenic effects. Mechanistic themes include suppression of NF-κB and PI3K/AKT signaling, modulation of MAPK pathways, induction of mitochondrial apoptosis, and context-dependent ROS elevation in tumor cells. Some studies report inhibition of HIF-1α and glycolytic signaling, though cinnamon is not a direct enzymatic Warburg inhibitor. Effects vary substantially depending on species (Ceylon vs Cassia), preparation (aqueous vs ethanol extract), and dose. Human oncology data remain limited and largely preclinical.

-Cinnamaldehyde (CA), an active compound derived from the natural plant cinnamon. CA is an aromatic aldehyde compound, constituting approximately 65% of cinnamon extract
- See also HCA, a derivative of CA

Biological activity, cinnamaldehyde from Ceylon cinnamon:
Antimicrobial activity: 10-50 μM
Antioxidant activity: 10-100 μM
Anti-inflammatory activity: 20-50 μM
Anticancer activity: 50-100 μM
Cardiovascular health: 20-50 μM

5 g of Ceylon cinnamon might contain roughly between 30 mg and 150 mg of cinnamaldehyde, with an approximate mid-range estimate of about 70 mg.
Assuming a moderate supplemental intake 50–200 mg of cinnamaldehyde, peak plasma levels might be anticipated in the vicinity of 1–10 μM.

Primary mechanisms (ranked):

  1. Suppression of inflammatory and survival signaling, especially NF-κB, AP-1, COX-2, PI3K/AKT, and related anti-apoptotic programs.
  2. Induction of mitochondrial apoptosis and cell-cycle arrest in cancer models.
  3. Anti-metastatic and anti-invasive effects linked to glycolysis/HK2 suppression, migration inhibition, and EMT-related signaling changes.
  4. Anti-angiogenic activity through VEGF/VEGFR2/HIF-1α and downstream MAPK signaling modulation.
  5. Redox modulation, with antioxidant/NRF2 activation in normal-cell stress contexts but ROS elevation and apoptosis in some tumor models.

Bioavailability / PK relevance: Cinnamon is compositionally variable; cinnamaldehyde is lipophilic, rapidly absorbed and metabolized, and systemic exposure after oral intake is likely much lower than many in-vitro anticancer concentrations. Extract formulation, species, dose, food matrix, and first-pass metabolism materially affect exposure.

In-vitro vs systemic exposure relevance: Many anticancer studies use extract concentrations or cinnamaldehyde levels that may exceed achievable free systemic exposure after ordinary oral intake. Local gastrointestinal exposure may be more plausible than systemic tumor exposure.

Clinical evidence status: Preclinical for oncology. Cinnamon has human RCT/meta-analysis literature mainly in metabolic/inflammatory endpoints, but no established clinical anticancer indication. Translational constraints include variable extract chemistry, cassia coumarin hepatotoxicity risk, CYP/herb-drug interaction potential, and uncertain tumor-achievable exposure.

Cinnamon Cancer Mechanism Table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 NF-κB AP-1 inflammatory survival signaling NF-κB ↓; AP-1 ↓; COX-2 ↓; Bcl-2 family survival tone ↓ Inflammatory tone ↓ R, G Anti-inflammatory and anti-survival signaling Core mechanism for cinnamon extract and cinnamaldehyde; model-dependent but repeatedly reported.
2 PI3K AKT mTOR growth signaling PI3K/AKT ↓; proliferation ↓; apoptosis ↑ ↔ or stress protection ↑ R, G Growth-signal suppression Most relevant for cinnamaldehyde-rich preparations; linked to colorectal and other cancer models.
3 Mitochondrial apoptosis Bax ↑; Bcl-2 ↓; mitochondrial dysfunction ↑; caspase activation ↑ ↔ at lower exposure; cytotoxicity risk at high exposure G Apoptotic induction Central anticancer mechanism but often requires concentrations above dietary exposure.
4 Glycolysis and HK2 driven invasion HK2 ↓; G6P/F6P production ↓; migration ↓; invasion ↓ ↔ G Anti-metastatic metabolic suppression Mechanistically important for metastatic dissemination models; not a broad direct Warburg enzyme inhibitor claim.
5 VEGF VEGFR2 HIF-1α angiogenesis axis VEGF ↓; HIF-1α ↓; angiogenesis ↓ Endothelial VEGFR2/MAPK signaling ↓ under angiogenic stimulation R, G Anti-angiogenic effect Supported by endothelial, tumor-cell, zebrafish, and mouse xenograft-style evidence.
6 ROS redox stress ROS ↑ and apoptosis ↑ in some tumor models (dose-dependent) ROS ↓ or antioxidant response ↑ at lower exposure P, R Context-dependent redox modulation Not simply antioxidant or pro-oxidant; direction depends on compound, dose, exposure time, and cell stress state.
7 NRF2 antioxidant response NRF2 ↑ may be protective or resistance-relevant (context-dependent) NRF2 ↑; cytoprotective gene expression ↑ R, G Stress-response activation Important safety/normal-cell protection axis; in cancer it may be double-edged if persistent NRF2 supports survival.
8 Cell-cycle regulation G1 or G2/M arrest ↑; cyclin/CDK signaling ↓ ↔ G Cytostasis Secondary to upstream growth and stress signaling changes.
9 MAPK stress signaling JNK/p38 modulation ↑; ERK modulation mixed ↔ or inflammatory MAPK ↓ P, R Signal reprogramming Direction varies by model and stimulus; best treated as contextual rather than primary.
10 Clinical Translation Constraint Systemic exposure uncertain; in-vitro dose gap likely Cassia coumarin hepatotoxicity risk; CYP interaction potential G Translation limitation Ceylon cinnamon is preferred for repeated higher intake because cassia generally has higher coumarin content.

TSF: P = 0–30 min (redox and early signaling effects), R = 30 min–3 hr (acute pathway modulation), G = >3 hr (apoptosis, angiogenesis, phenotype changes).



Scientific Papers found: Click to Expand⟱
3892- Cin,    Cinnamon from the selection of traditional applications to its novel effects on the inhibition of angiogenesis in cancer cells and prevention of Alzheimer's disease, and a series of functions such as antioxidant, anticholesterol, antidiabetes, antibacterial, antifungal, nematicidal, acaracidal, and repellent activities
- Review, AD, NA - Review, Var, NA
*antiOx↑, *Inflam↓, *cardioP↑, angioG↓, VEGF↓, *LDL↓, COX2↓, Hif1a↓, *Aβ↓, *tau↓, *toxicity↓,
6145- Cin,    Cinnamaldehyde microcapsules enhance bioavailability and regulate intestinal flora in mice
- in-vivo, Nor, NA
BioAv↑, GutMicro↑,
6144- Cin,    The Cinnamon-Derived Dietary Factor Cinnamic Aldehyde Activates the Nrf2-Dependent Antioxidant Response in Human Epithelial Colon Cells
- in-vitro, Colon, HCT116
Nrf1↑, HO-1↑, chemoPv↑,
6143- Cin,    Novel angiogenesis inhibitory activity in cinnamon extract blocks VEGFR2 kinase and downstream signaling
- in-vitro, Var, NA
VEGFR2↓, angioG↓,
6142- Cin,    Cinnamaldehyde affects the biological behavior of human colorectal cancer cells and induces apoptosis via inhibition of the PI3K/Akt signaling pathway
- in-vitro, CRC, LoVo - in-vitro, CRC, SW48 - in-vitro, CRC, HCT116
E-cadherin↑, MMP2↓, MMP9↓, PI3K↓, Akt↓, IGF-1↓, Apoptosis↑, BAX↑, cl‑PARP↑, PARP↓, Bcl-2↓, TumCI↓,
6141- Cin,    The role and mechanism of cinnamaldehyde in cancer
- Review, Var, NA
Apoptosis↑, Casp↑, mtDam↑, angioG↓, TumCP↓, *Inflam↓, *antiOx↑, *ROS↓, *DNAdam↓, ROS↑, *Bcl-2↑, *BAX↓, *NF-kB↓, ChemoSen↑, ICAM-1↓, VCAM-1↓, PI3K↓, Akt↓, mTOR↓, BioAv↝,
6140- Cin,  HCAs,    Cinnamaldehyde: Pharmacokinetics, anticancer properties and therapeutic potential (Review)
- Review, Var, NA
Dose↝, TumCP↓, TumCCA↑, Apoptosis↑, TumCMig↓, TumCI↓, angioG↓, *Inflam↓, *antiOx↑, *Bacteria↓, *AntiThr↑, *hepatoP↑, *AntiDiabetic↑, *neuroP↑, AntiCan↑, ChemoSen↑, *BioAv↝, *BioAv↑, eff↑, CDK1↓, CDK2↓, CDK4↓, cJun↓, cFos↓, Apoptosis↑, PI3K↓, Akt↓, E-cadherin↑, MMP2↓, MMP9↓, TOP1↓, BRCA1↓, ROS↑, BAX↑, Bcl-2↓, XIAP↓, MMP↓, STAT3↓, mTOR↓, NF-kB↓, eff↑, toxicity↓, cardioP↑,
4259- Cin,    The Potential of Cinnamon as Anti-Depressant
- Review, NA, NA
*Inflam↓, *BDNF↑, *TNF-α↓, *lipid-P↓, *Mood↑,
3894- Cin,    Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis
- in-vitro, AD, NA
*tau↓, *ROS↓,
3893- Cin,    Cinnamon extract inhibits tau aggregation associated with Alzheimer's disease in vitro
- Review, AD, NA
*tau↓, *toxicity↓,
952- Cin,    Cinnamon Extract Reduces VEGF Expression Via Suppressing HIF-1α Gene Expression and Inhibits Tumor Growth in Mice
- in-vitro, BC, MDA-MB-231 - in-vitro, GBM, U251 - in-vivo, Ovarian, SKOV3
VEGF↓, Hif1a↓, p‑STAT3↓, p‑Akt↓, angioG↓, TumCG↓, TumW↓, ascitic↓,
3891- Cin,    Identification of potential targets of cinnamon for treatment against Alzheimer's disease-related GABAergic synaptic dysfunction using network pharmacology
- Analysis, AD, NA
*BBB↑, *GABA↑, *eff↑, *antiOx↑, *Inflam↑, *Mood↑,
3890- Cin,    The Therapeutic Roles of Cinnamaldehyde against Cardiovascular Diseases
- Review, NA, NA
*cardioP↑, *Inflam↓, *ROS↓, *lipid-P↓, *AntiAg↑, *angioG↑, *GutMicro↑, *ER Stress↓,
3889- Cin,    Orally administrated cinnamon extract reduces β-amyloid oligomerization and corrects cognitive impairment in Alzheimer's disease animal models
- in-vivo, AD, NA
*Aβ↓, *cognitive↑, *tau↓,
3888- Cin,    Cinnamon, a promising prospect towards Alzheimer's disease
- NA, AD, NA
*tau↓, *Aβ↓, *neuroP↑, *ROS↓, *Inflam↓, *cardioP↑, *antiOx↑, *cognitive↑, *BBB↑, *p‑GSK‐3β↑, *AChE↓,
1568- Cin,    Can Cinnamon be the Silver Bullet for Cancer?
- Review, NA, NA
VEGF↓, Hif1a↓,
1567- Cin,    Cinnamon: Mystic powers of a minute ingredient
- Review, Var, NA
other∅, cognitive↑, antiOx↑, lipid-P↓, Apoptosis↑, NF-kB↓,
1274- Cin,    Cinnamon bark extract suppresses metastatic dissemination of cancer cells through inhibition of glycolytic metabolism
- vitro+vivo, BC, MDA-MB-231
TumCI↓, G6PD↓, HK2↓, Glycolysis↓,
1055- Cin,    Cinnamon extract induces tumor cell death through inhibition of NFκB and AP1
- vitro+vivo, Melanoma, NA - vitro+vivo, CRC, NA - vitro+vivo, lymphoma, NA
TumCP↓, NF-kB↓, AP-1↓, Bcl-2↓, Bcl-xL↓, survivin↓,

Showing Research Papers: 1 to 19 of 19

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 19

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   HO-1↑, 1,   lipid-P↓, 1,   Nrf1↑, 1,   ROS↑, 2,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,   mtDam↑, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

G6PD↓, 1,   Glycolysis↓, 1,   HK2↓, 1,  

Cell Death ⓘ

Akt↓, 3,   p‑Akt↓, 1,   Apoptosis↑, 5,   BAX↑, 2,   Bcl-2↓, 3,   Bcl-xL↓, 1,   Casp↑, 1,   survivin↓, 1,  

Transcription & Epigenetics ⓘ

cJun↓, 1,   other∅, 1,  

DNA Damage & Repair ⓘ

BRCA1↓, 1,   PARP↓, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↓, 1,   CDK4↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

cFos↓, 1,   IGF-1↓, 1,   mTOR↓, 2,   PI3K↓, 3,   STAT3↓, 1,   p‑STAT3↓, 1,   TOP1↓, 1,   TumCG↓, 1,  

Migration ⓘ

AP-1↓, 1,   E-cadherin↑, 2,   MMP2↓, 2,   MMP9↓, 2,   TumCI↓, 3,   TumCMig↓, 1,   TumCP↓, 3,   VCAM-1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 5,   Hif1a↓, 3,   VEGF↓, 3,   VEGFR2↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   ICAM-1↓, 1,   NF-kB↓, 3,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   BioAv↝, 1,   ChemoSen↑, 2,   Dose↝, 1,   eff↑, 2,  

Clinical Biomarkers ⓘ

ascitic↓, 1,   BRCA1↓, 1,   GutMicro↑, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   cardioP↑, 1,   chemoPv↑, 1,   cognitive↑, 1,   toxicity↓, 1,   TumW↓, 1,  
Total Targets: 65

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 5,   lipid-P↓, 2,   ROS↓, 4,  

Core Metabolism/Glycolysis ⓘ

LDL↓, 1,  

Cell Death ⓘ

BAX↓, 1,   Bcl-2↑, 1,  

Transcription & Epigenetics ⓘ

AntiThr↑, 1,  

Protein Folding & ER Stress ⓘ

ER Stress↓, 1,  

DNA Damage & Repair ⓘ

DNAdam↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

p‑GSK‐3β↑, 1,  

Migration ⓘ

AntiAg↑, 1,  

Angiogenesis & Vasculature ⓘ

angioG↑, 1,  

Barriers & Transport ⓘ

BBB↑, 2,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 6,   Inflam↑, 1,   NF-kB↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,   BDNF↑, 1,   GABA↑, 1,   tau↓, 5,  

Protein Aggregation ⓘ

Aβ↓, 3,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   BioAv↝, 1,   eff↑, 1,  

Clinical Biomarkers ⓘ

GutMicro↑, 1,  

Functional Outcomes ⓘ

AntiDiabetic↑, 1,   cardioP↑, 3,   cognitive↑, 2,   hepatoP↑, 1,   Mood↑, 2,   neuroP↑, 2,   toxicity↓, 2,  

Infection & Microbiome ⓘ

Bacteria↓, 1,  
Total Targets: 34

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:62  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page